Wyzer Biosciences

Wyzer Biosciences is a privately held, revenue-generating service provider in the genomics space, operating since 2011. The company's core business is providing end-to-end DNA sequencing and prep services to research institutions, positioning itself as a specialized, customer-centric alternative to larger, less personalized CROs. While its website mentions sectors like AI/Machine Learning and Drug Delivery, its current, demonstrable operations are squarely in the sequencing services domain. Its strategic location in Cambridge provides access to a dense network of academic and biotech clients, though its technology platform and therapeutic pipeline appear undeveloped or not publicly disclosed.

Operational expertise in Sanger and Next-Generation Sequencing (NGS) services and sample preparation. Claims of AI/ML and Drug Delivery capabilities are not detailed in public materials.

Competes directly with other sequencing service providers, ranging from large global CROs (e.g., Eurofins, Charles River Labs' subsidiary businesses) to university core facilities and small regional shops. Differentiation is based on service quality, turnaround time, price, and personalized customer support rather than proprietary technology.